27-01-12
OctoPlus publishes Prospectus for listing of shares issued on 31 October 2011

OctoPlus N.V. (“OctoPlus”, or the “Company”) (Euronext: OCTO) publishes today a prospectus for the admission to listing and trading on Euronext Amsterdam by NYSE Euronext (“Euronext Amsterdam”) of 8,000,000 newly issued ordinary shares as per 27 January 2012 (the “Prospectus”). The shares were issued in the context of the private placement that OctoPlus successfully completed on 31 October 2011 which raised € 4.0 million gross from new and existing investors (the “Offering”). The proceeds of this financing will be used for working capital purposes and for high value opportunities with upside potential such as specialty generics.

It should be noted that the Prospectus contains a qualified working capital statement which states that OctoPlus has not secured sufficient working capital for its present requirements, being the next 12 months from the date of this Prospectus. The company has a gradually improving negative operational cash flow, continuing during the first half of 2012. The Company is confident that it will be able to generate sufficient funds to continue its business for the next 12 months from the date of this Prospectus by its mitigating action plan, as further detailed in the Prospectus. The Prospectus was approved by the Netherlands Authority for the Financial Markets (AFM) on 24 January 2012. The Prospectus is available in the Investor Relations section on the Company’s website: www.octoplus.nl.

Financial calendar 2012

OctoPlus also announces that it will publish its annual results for the year 2011 on Friday 17 February, which will be discussed in a conference call and webcast at 10:00 AM that day.

Contact

For further information about OctoPlus, please contact Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or send an e-mail to Investor Relations at IR[at]octoplus[dot]nl.

About OctoPlus

OctoPlus is a specialty pharmaceutical company focused on the development and manufacture of improved injectable pharmaceuticals based on our proprietary drug delivery technologies that exhibit fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. OctoPlus also focuses on the development of long-acting, controlled release versions of known protein therapeutics, peptides and small molecules, including specialty generics.

The clinically most advanced product incorporating our technology is Locteron®, a controlled release formulation of interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus and has recently completed Phase IIb clinical studies with superior clinical data versus current treatment.

In addition, OctoPlus is a leading European provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industries, with a focus on difficult-to-formulate active pharmaceutical ingredients.

OctoPlus is listed on NYSE Euronext in Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

Source: Octoplus
Biotech Company Profile
OctoPlus N.V.
Zernikedreef 12, 2333 CL, Leiden
Phone: +31 (71) 5244044, www.octoplus.nl
Sector: Biotechnology - Therapeutics
Description: OctoPlus is a drug product development services company that is globally renowned as a center of excellence in formulation development, drug delivery and GMP manufacturing of injectables. OctoPlus offers: -1- Drug formulation development services (including analytical development and manufacturing process development), -2- cGMP manufacturing, and -3- Controlled release technologies.